Combined poly(isobutylcyanoacrylate) and cyclodextrins nanoparticles for enhancing the encapsulation of lipophilic drugs

Pharmaceutical Research

Volumn 15, Issue 7, 1998, Pages 1051-1055

  Da Silveira, Airton Monza ^a,b   Ponchel, Gilles ^a   Puisieux, Francis ^a   Duchêne, Dominique ^a  

^a CNRS   (France)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Cyclodextrins; Drug loading; Hydroxypropyl cyclodextrin; Nanoparticles; Poly(isobutylcyanoacrylate); Progesterone

Indexed keywords

CYCLODEXTRIN; NANOPARTICLE; POLY(ISOBUTYL 2 CYANOACRYLATE); PROGESTERONE;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG MANUFACTURE; ENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL;

BETA-CYCLODEXTRINS; BUCRYLATE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLODEXTRINS; DRUG CARRIERS; PARTICLE SIZE; PROGESTERONE; SURFACE-ACTIVE AGENTS;

EID: 0347090152     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011982211632     Document Type: Article

References (14)

1. J. Kreuter. Nanoparticles. In J. Kreuter (ed.), Colloidal Drug Delivery, Systems, Marcel Decker, New York, 1994, pp. 219-342.
2. P. Couvreur, M. Roland, and P. Speiser. Biodegradable submicronic particles containing a biologically active substance and compositions containing then. U.S. Patent No 4, 329-332, 1982.
3. M. Vikmon. Rapid and simple spectrophotometric method for determination of micro-amounts of cyclodextrins. Proceed. First International Symposium in Cyclodextrins, Budapest, 69-74, 1981.
4. S. J. Douglas, L. Illum, and S. Davis. Particle size distribution of poly(butyl 2-cyanoacrylate) nanoparticles. J. Colloid. Interf. Sci. 103:154-163 (1985).
5. C. Lourenço, M. Teixeira, S. Simões, and R. Gaspar. Steric stabilization of nanoparticles: size and surface properties. Int. J. Pharm. 138:1-12 (1996).
6. F. W. Lichtenthaller and S. Immel. The lipophilicity patterns of cyclodextrins and of non-glucose cyclooligosaccharides. Proceed. Eigth International Symposium of Cyclodextrins, 3-16, 1996.
7. M. Gallardo, G. Couarraze, B. Denizot, L. Treupel, P. Couvreur, and F. Puisieux. Study of the mecanisms of formation of nanoparticles and nanocapsules of polyisobutyl-2-cyanoacrylate. Int. J. Pharm. 100:55-64 (1993).
8. C. Verdun, P. Couvreur, H. Vranckx, V. Lenaerts, and M. Roland. Development of a nanoparticle controlled-release formulation for human use. J. Control. Rel. 3:205-210 (1986).
9. M. Fresta and G. Puglisi. Association of netilmicin sulphate to poly(alkylcyanoacrylate) nanoparticles: Factors influencing particle delivery behaviour. Drug Dev. Ind. Pharm, 20:2227-2243 (1994).
10. B. Seijo, E. Fattal L. Roblot-Treupel, and P. Couvreur. Design of nanoparticles of less than 50 nm diameter: preparation, characterization and drug loading. Int. J. Pharm. 62:1-7 (1990).
11. Ch. Tasset, N. Barette, S. Thysman, J. M. Ketelsgers, D. Lemoine, and V. Préat. Polyisobutylcyanoacrylate nanoparticles as sustained release system for calcitonin. J. Control. Rel. 33:23-30 (1995).
12. V. H. K. Li, R. Wood, J. Kreuter, T. Harmia, and J. Robinson. Ocular drug delivery of progesterone using nanoparticles. J. Microencapsul. 3:213-218 (1986).
13. S.-Z. Lin, M. Skiba D. Wouessidjewe, B. Agnus, and D. Duchêne. Inclusion complexes of progesterone and its analogue x with cyclodextrins. Proceed. 6th International Symposium on Cyclodextrins, Chicago, U.S.A., 460-465, 1992.
14. M.-C. Venier-Julienne and J. P. Benoit. Preparation, purification and morphology of polymeric nanoparticles as drug carriers. Pharmaceutica Acta Helvetiae, 7:121-128 (1996).